A synthetic peptide derived from domain III envelope glycoprotein of Dengue virus induces neutralizing antibody
- 25 September 2017
- journal article
- research article
- Published by Springer Nature in Virus Genes
- Vol. 54 (1) , 25-32
Abstract
Dengue virus (DENV) is an arthropod-borne human pathogen that represents a severe public health threat in both endemic and non-endemic regions. So far, there is no licensed vaccine or specific drugs available for dengue fever. A fifteen-amino-acid-long peptide that includes the NGR motif was chemically synthesized and conjugated with keyhole limpet hemocyanin. A standard immunization protocol was followed for the production of polyclonal antibodies by immunizing rabbits against the synthetic peptide. The immune response elicited high-titer polyclonal antibodies with the reactivity of the anti-peptide antibody against both synthetic peptide and four serotypes of DENV confirmed by DOT-ELISA. Neutralizing activity of anti-peptide antibody was found to be cross-reactive and effective resulting in 60% reduction of infectivity at 1:200 dilution in all four serotypes of DENV. Our findings have the potential to further improve our understanding of virus–host interactions and provide new insights into neutralizing antibodies and could also be used as a drug target.Keywords
Funding Information
- DBT-BIF (BT/BI/25/017/2012)
This publication has 23 references indexed in Scilit:
- Structural Analysis of a Dengue Cross-Reactive Antibody Complexed with Envelope Domain III Reveals the Molecular Basis of Cross-ReactivityThe Journal of Immunology, 2012
- Structure and Function Analysis of Therapeutic Monoclonal Antibodies against Dengue Virus Type 2Journal of Virology, 2010
- The Mannose Receptor Mediates Dengue Virus Infection of MacrophagesPLOS Pathogens, 2008
- Essential Role of Dengue Virus Envelope Protein N Glycosylation at Asparagine-67 during Viral PropagationJournal of Virology, 2007
- Up-regulated expression of β3 integrin induced by dengue virus serotype 2 infection associated with virus entry into human dermal microvascular endothelial cellsBiochemical and Biophysical Research Communications, 2007
- Identification and Characterization of Carbohydrate Molecules in Mammalian Cells Recognized by Dengue Virus Type 2The Journal of Biochemistry, 2006
- Serotype-Specific Entry of Dengue Virus into Liver Cells: Identification of the 37-Kilodalton/67-Kilodalton High-Affinity Laminin Receptor as a Dengue Virus Serotype 1 ReceptorJournal of Virology, 2004
- DC-SIGN (CD209) Mediates Dengue Virus Infection of Human Dendritic CellsJournal of Experimental Medicine, 2003
- Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero CellsJournal of Virology, 2001
- Biophysical Characterization and Vector-Specific Antagonist Activity of Domain III of the Tick-Borne Flavivirus Envelope ProteinJournal of Virology, 2001